Report of the american Heart association (AHA) scientific sessions 2014, Chicago

Takashi Kohno

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The American Heart Association (AHA) Scientific Sessions were held in Chicago on November 15–19, 2014. The meeting attracted more than 17,000 participants, including physicians, research scientists, students, and paramedical personnel, from more than 100 countries. Sessions over the 5 days included comprehensive and unparalleled education delivered via more than 5,000 presentations, with 1,000 invited faculty members and 4,000 abstract presentations from world leaders in cardiovascular (CV) disease. There were 16 trials scheduled in 4 late-breaking clinical trial sessions. The Dual Antiplatelet Therapy study revealed that aspirin plus a thienopyridine beyond 1 year subsequent to placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced stent thrombosis and major CV and cerebrovascular events but was associated with increased risk of bleeding. The IMPROVE-IT research showed that, relative to simvastatin with placebo, simvastatin with 10 mg of ezetimibe daily led to a sign icantly lower primary combined endpoint in moderateto high-risk patients, who stabilized following acute coronary syndrome. This was the first trial to demonstrate incremental clinical benefit by adding a nonstatin agent to statin therapy and reaffirmed the low-density lipoprotein (LDL) hypothesis stating that reducing LDL-cholesterol prevents CV events. Summaries and overviews of both the late-breaking trials and the sessions to which members of the Japanese Circulation Society contributed are presented.

Original languageEnglish
Pages (from-to)34-40
Number of pages7
JournalCirculation Journal
Volume79
Issue number1
DOIs
Publication statusPublished - 2014 Dec 19

Fingerprint

American Heart Association
Simvastatin
Aspirin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Allied Health Personnel
Drug-Eluting Stents
Acute Coronary Syndrome
LDL Lipoproteins
Research
LDL Cholesterol
Stents
Thrombosis
Cardiovascular Diseases
Therapeutics
Placebos
Clinical Trials
Hemorrhage
Students
Physicians
Education

Keywords

  • American Heart Association
  • Japanese Circulation Society
  • Late-breaking clinical trials
  • Scientific Sessions

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Report of the american Heart association (AHA) scientific sessions 2014, Chicago. / Kohno, Takashi.

In: Circulation Journal, Vol. 79, No. 1, 19.12.2014, p. 34-40.

Research output: Contribution to journalArticle

@article{ee3bedafcade40179ac6207b5939d1da,
title = "Report of the american Heart association (AHA) scientific sessions 2014, Chicago",
abstract = "The American Heart Association (AHA) Scientific Sessions were held in Chicago on November 15–19, 2014. The meeting attracted more than 17,000 participants, including physicians, research scientists, students, and paramedical personnel, from more than 100 countries. Sessions over the 5 days included comprehensive and unparalleled education delivered via more than 5,000 presentations, with 1,000 invited faculty members and 4,000 abstract presentations from world leaders in cardiovascular (CV) disease. There were 16 trials scheduled in 4 late-breaking clinical trial sessions. The Dual Antiplatelet Therapy study revealed that aspirin plus a thienopyridine beyond 1 year subsequent to placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced stent thrombosis and major CV and cerebrovascular events but was associated with increased risk of bleeding. The IMPROVE-IT research showed that, relative to simvastatin with placebo, simvastatin with 10 mg of ezetimibe daily led to a sign icantly lower primary combined endpoint in moderateto high-risk patients, who stabilized following acute coronary syndrome. This was the first trial to demonstrate incremental clinical benefit by adding a nonstatin agent to statin therapy and reaffirmed the low-density lipoprotein (LDL) hypothesis stating that reducing LDL-cholesterol prevents CV events. Summaries and overviews of both the late-breaking trials and the sessions to which members of the Japanese Circulation Society contributed are presented.",
keywords = "American Heart Association, Japanese Circulation Society, Late-breaking clinical trials, Scientific Sessions",
author = "Takashi Kohno",
year = "2014",
month = "12",
day = "19",
doi = "10.1253/circj.CJ-14-1329",
language = "English",
volume = "79",
pages = "34--40",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "1",

}

TY - JOUR

T1 - Report of the american Heart association (AHA) scientific sessions 2014, Chicago

AU - Kohno, Takashi

PY - 2014/12/19

Y1 - 2014/12/19

N2 - The American Heart Association (AHA) Scientific Sessions were held in Chicago on November 15–19, 2014. The meeting attracted more than 17,000 participants, including physicians, research scientists, students, and paramedical personnel, from more than 100 countries. Sessions over the 5 days included comprehensive and unparalleled education delivered via more than 5,000 presentations, with 1,000 invited faculty members and 4,000 abstract presentations from world leaders in cardiovascular (CV) disease. There were 16 trials scheduled in 4 late-breaking clinical trial sessions. The Dual Antiplatelet Therapy study revealed that aspirin plus a thienopyridine beyond 1 year subsequent to placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced stent thrombosis and major CV and cerebrovascular events but was associated with increased risk of bleeding. The IMPROVE-IT research showed that, relative to simvastatin with placebo, simvastatin with 10 mg of ezetimibe daily led to a sign icantly lower primary combined endpoint in moderateto high-risk patients, who stabilized following acute coronary syndrome. This was the first trial to demonstrate incremental clinical benefit by adding a nonstatin agent to statin therapy and reaffirmed the low-density lipoprotein (LDL) hypothesis stating that reducing LDL-cholesterol prevents CV events. Summaries and overviews of both the late-breaking trials and the sessions to which members of the Japanese Circulation Society contributed are presented.

AB - The American Heart Association (AHA) Scientific Sessions were held in Chicago on November 15–19, 2014. The meeting attracted more than 17,000 participants, including physicians, research scientists, students, and paramedical personnel, from more than 100 countries. Sessions over the 5 days included comprehensive and unparalleled education delivered via more than 5,000 presentations, with 1,000 invited faculty members and 4,000 abstract presentations from world leaders in cardiovascular (CV) disease. There were 16 trials scheduled in 4 late-breaking clinical trial sessions. The Dual Antiplatelet Therapy study revealed that aspirin plus a thienopyridine beyond 1 year subsequent to placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced stent thrombosis and major CV and cerebrovascular events but was associated with increased risk of bleeding. The IMPROVE-IT research showed that, relative to simvastatin with placebo, simvastatin with 10 mg of ezetimibe daily led to a sign icantly lower primary combined endpoint in moderateto high-risk patients, who stabilized following acute coronary syndrome. This was the first trial to demonstrate incremental clinical benefit by adding a nonstatin agent to statin therapy and reaffirmed the low-density lipoprotein (LDL) hypothesis stating that reducing LDL-cholesterol prevents CV events. Summaries and overviews of both the late-breaking trials and the sessions to which members of the Japanese Circulation Society contributed are presented.

KW - American Heart Association

KW - Japanese Circulation Society

KW - Late-breaking clinical trials

KW - Scientific Sessions

UR - http://www.scopus.com/inward/record.url?scp=84924628161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924628161&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-14-1329

DO - 10.1253/circj.CJ-14-1329

M3 - Article

VL - 79

SP - 34

EP - 40

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 1

ER -